Hotchkis & Wiley Capital Management
IRWD icon

Hotchkis & Wiley Capital Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Hotchkis & Wiley Capital Management’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,140,470
Closed -$13M – 504
2023
Q4 		$13M Buy
1,140,470
+43,800
+4% +$433K 0.05% 150
2023
Q3 		$10.6M Buy
1,096,670
+99,840
+10% +$979K 0.04% 183
2023
Q2 		$10.6M Buy
996,830
+54,670
+6% +$588K 0.04% 180
2023
Q1 		$9.91M Buy
942,160
+148,640
+19% +$1.67M 0.04% 174
2022
Q4 		$9.83M Buy
793,520
+404,140
+104% +$4.58M 0.04% 164
2022
Q3 		$4.03M Buy
+389,380
New +$4.41M 0.02% 356

Other funds holding IRWD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Hotchkis & Wiley Capital Management's IRWD Position: Q1 2024 in Review

Hotchkis & Wiley Capital Management sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2024, closing a stake of 1,140,470 shares — an estimated $13M sold.

Hotchkis & Wiley Capital Management first reported a position in IRWD in Q3 2022 and held it in 6 quarters. The position peaked at $13M in Q4 2023. 261 funds tracked by Wall St. Rank hold IRWD as of Q1 2024.

  • Hotchkis & Wiley Capital Management reported no remaining Ironwood Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Hotchkis & Wiley Capital Management sold 1,140,470 Ironwood Pharmaceuticals shares in Q1 2024, an estimated $13M.
  • Hotchkis & Wiley Capital Management first reported a position in Ironwood Pharmaceuticals in Q3 2022 and held it in 6 quarters.
  • Hotchkis & Wiley Capital Management's Ironwood Pharmaceuticals position peaked at $13M in Q4 2023.
  • 261 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2024.

Based on Hotchkis & Wiley Capital Management's 13F filing for Q1 2024, filed 14 May 2024.